BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Cetrelimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Cetrelimab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04658862-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT04658862)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in P
 articipants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder\nEst
 imated primary completion: 30 December 2026. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04658862
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05908734-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Cetrelimab: Phase 1/2 readout est. (NCT05908734)
DESCRIPTION:Cetrelimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Study of Combination Therapy With Amivantamab and Cetrelimab in Participan
 ts With Metastatic Non-small Cell Lung Cancer\nEstimated primary completio
 n: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/c
 etrelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05908734
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06116786-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270414
DTEND;VALUE=DATE:20270415
SUMMARY:Cetrelimab: Phase 1 readout est. (NCT06116786)
DESCRIPTION:Cetrelimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Canc
 er\nEstimated primary completion: 14 April 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06116786
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027514-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Cetrelimab: Phase 1 readout est. (NCT07027514)
DESCRIPTION:Cetrelimab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 A
 ntibody in Participants With Advanced Non-Small Cell Lung Cancer\nEstimate
 d primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07027514
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05818683-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cetrelimab: Phase 1 readout est. (NCT05818683)
DESCRIPTION:Cetrelimab\, phase 1.\nStudy: A Study of Pasritamig (JNJ-782783
 43) in Combination With Other Agents for Metastatic Prostate Cancer\nEstim
 ated primary completion: 31 August 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05818683
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04592237-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cetrelimab: Phase 2 readout est. (NCT04592237)
DESCRIPTION:Cetrelimab\, phase 2.\nStudy: Cabazitaxel\, Carboplatin\, and C
 etrelimab Followed by Niraparib With or Without Cetrelimab for the Treatme
 nt of Aggressive Variant Metastatic Prostate Cancer\nEstimated primary com
 pletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/cetrelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04592237
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525141-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20280112
DTEND;VALUE=DATE:20280113
SUMMARY:Cetrelimab: Phase 1 readout est. (NCT07525141)
DESCRIPTION:Cetrelimab\, phase 1.\nStudy: A Study of JNJ-1761981 in Partici
 pants With Solid Tumors\nEstimated primary completion: 12 January 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/cetrelimab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07525141
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06534190-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Cetrelimab: Phase 2 readout est. (NCT06534190)
DESCRIPTION:Cetrelimab\, phase 2.\nStudy: CD8 PET Imaging in Metastatic Sol
 id Tumours\nEstimated primary completion: November 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cetrelimab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06534190
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06311578-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Cetrelimab: Phase 1 readout est. (NCT06311578)
DESCRIPTION:Cetrelimab\, phase 1.\nStudy: A Study of JNJ-87704916\, as Mono
 therapy and in Combination for Advanced Solid Tumors\nEstimated primary co
 mpletion: 8 November 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/cetrelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06311578
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05714202-2285@assetmemo.bio
DTSTAMP:20261121T004024Z
DTSTART;VALUE=DATE:20290918
DTEND;VALUE=DATE:20290919
SUMMARY:Cetrelimab: Phase 3 readout est. (NCT05714202)
DESCRIPTION:Cetrelimab\, phase 3\, Bladder Cancer.\nStudy: A Study of TAR-2
 00 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bac
 illus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non
 -muscle Invasive Bladder Cancer (HR-NMIBC)\nEstimated primary completion: 
 18 September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ce
 trelimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05714202
URL:https://assetmemo.bio/drug/cetrelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
